Fig. 5: BKM120/rucaparib combination treatment markedly reduced tumor growth in U87MG nude mouse heterotopic xenograft models. | Cell Death & Disease

Fig. 5: BKM120/rucaparib combination treatment markedly reduced tumor growth in U87MG nude mouse heterotopic xenograft models.

From: BKM120 sensitizes glioblastoma to the PARP inhibitor rucaparib by suppressing homologous recombination repair

Fig. 5

A–H Nude mice with subcutaneous U87MG tumors were treated with vehicle, BKM120 (15 mg/kg), rucaparib (4 mg/kg), or the BKM120/rucaparib combination for 16 days (n = 7). After sacrificing mice, images were taken as shown in (A). Then, tumors were taken from mice with the pictures indicated in (B). C Measurement of tumor weight. Time-course measurements of tumor volumes (D) and body weights (E) every 3 days. F H&E and Ki67 immunohistochemistry staining of tumor tissues from U87MG xenograft mice treated with BKM120 and/or rucaparib. Scale bar: 50 μm. G Statistical quantification of (F) shows U87MG cell proliferation in xenografts with the indicated treatments. H western blotting analysis of BRCA1 and γ-H2AX in harvested tumors. Data are presented as the mean ± SD (n = 3). *P < 0.05; **P < 0.01; ***P < 0.001.

Back to article page